Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Papi

Showing results (331-340 of 430) with videos related to

Pageof 43
Sort By:
Molecular Oncology|May 23, 2020
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancerRoberta Roncarati, Laura Lupini, Elena Miotto, et al.
The Journal of Allergy and Clinical Immunology|April 14, 2020
Bronchial mucosal inflammation and illness severity in response to experimental rhinovirus infection in COPDJie Zhu, Patrick Mallia, Joseph Footitt, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 25, 2022
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle FluticasoneDavid B Price, William Henley, José Eduardo Delfini Cançado, et al.
The Lancet. Respiratory Medicine|July 12, 2025
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trialStephanie A Christenson, Nicola A Hanania, Surya P Bhatt, et al.
Chest|February 2, 2025
Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUSSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
The Lancet. Respiratory Medicine|December 9, 2024
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trialDave Singh, Christopher E Brightling, Klaus F Rabe, et al.
Respiratory Medicine|October 31, 2024
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)Surya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
The European Respiratory Journal|December 14, 2022
Development of a tool to detect small airways dysfunction in asthma clinical practiceJanwillem Kocks, Thys van der Molen, Jaco Voorham, et al.
The New England Journal of Medicine|April 30, 2025
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic PhenotypeFrank C Sciurba, Gerard J Criner, Stephanie A Christenson, et al.
Critical Care (London, England)|February 20, 2021
Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patientsSavino Spadaro, Alberto Fogagnolo, Gianluca Campo, et al.
Pageof 43

Showing results (331-340 of 430) with videos related to

Sort By:
Pageof 43
Molecular Oncology|May 23, 2020
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancerRoberta Roncarati, Laura Lupini, Elena Miotto, et al.
The Journal of Allergy and Clinical Immunology|April 14, 2020
Bronchial mucosal inflammation and illness severity in response to experimental rhinovirus infection in COPDJie Zhu, Patrick Mallia, Joseph Footitt, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 25, 2022
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle FluticasoneDavid B Price, William Henley, José Eduardo Delfini Cançado, et al.
The Lancet. Respiratory Medicine|July 12, 2025
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trialStephanie A Christenson, Nicola A Hanania, Surya P Bhatt, et al.
Chest|February 2, 2025
Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUSSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
The Lancet. Respiratory Medicine|December 9, 2024
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trialDave Singh, Christopher E Brightling, Klaus F Rabe, et al.
Respiratory Medicine|October 31, 2024
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)Surya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
The European Respiratory Journal|December 14, 2022
Development of a tool to detect small airways dysfunction in asthma clinical practiceJanwillem Kocks, Thys van der Molen, Jaco Voorham, et al.
The New England Journal of Medicine|April 30, 2025
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic PhenotypeFrank C Sciurba, Gerard J Criner, Stephanie A Christenson, et al.
Critical Care (London, England)|February 20, 2021
Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patientsSavino Spadaro, Alberto Fogagnolo, Gianluca Campo, et al.
Pageof 43